The absence of any effective combinatorial therapy in patients progressing on bevacizumab and evidence supporting both continuation and discontinuation of bevacizumab in this setting remain important areas for additional clinical trial evaluation in order to better guide our therapeutic decision making in the clinic.
A new genetic analysis found five new genetic variants that raise the risk for gliomas. One of the five was associated with a sharply increased risk for glioblastoma.
A genomic analysis of the primary tumors and brain metastases of patients has revealed potentially targetable mutations only present in the brain metastases.
A new meta-analysis found that adiposity is linked to an increased risk of meningioma, but is unrelated to glioma risk; and physical activity is linked to a lower risk for meningioma.
Gross total resection was associated with significantly lower all-cause mortality in patients with atypical and malignant meningioma, according to a new study.
Often excluded from early trials, adults with high-grade gliomas may be good candidates for solid tumor phase I studies of single agents, according to a new analysis.
Whole brain radiation therapy helps control tumor growth in patients with 1 to 3 small brain metastases, but it does not significantly extend patient survival.
Meningiomas are the most common primary brain tumor and comprise nearly one-third of all newly diagnosed primary brain tumors.
Childhood cancer patients treated with brain irradiation may be at a higher risk for developing into obese adults, according to a new study.
Conventional methods for treating brain metastasis, such as surgery, WBRT, and SRS, each compete with and complement one another. A plethora of recent studies have helped define and expand the utility of these tools.
It is time to put aside the pessimism of the past when it comes to brain metastases and embrace the wide array of clinical investigational opportunities arising in this field.
Some targeted systemic therapies have demonstrated evidence of activity in the brain-specifically in melanoma, lung cancers, and breast cancers-and these agents warrant further study in clinical trials.
There is no evidence that PCV is more effective than TMZ for the treatment of glioblastoma. However, there is unequivocal evidence that PCV is more toxic than TMZ.
In most cases, PCV chemotherapy will provide an edge in outcomes over TMZ for glioma patients, primarily because of the former regimen’s use of multiple drugs and their complementary interactions.
The US Food and Drug Administration has approved dinutuximab (Unituxin) for the treatment of high-risk neuroblastoma in pediatric patients.
Expression of the IGF2BP1 gene was associated with more advanced tumors and decreased patient survival in neuroblastoma, suggesting its prognostic value.
Researchers have shown that reprogramming T cells to target glioblastoma in mice resulted in control of these tumors.
A new study finds that childhood cancer survivors are at risk for pituitary hormone deficiencies after radiotherapy treatment to the head.
Stable, long-term survivors of low-grade glioma were able to maintain a high level of quality of life, but did experience detectable declines in certain areas.
Researchers have identified two genetic characteristics that may distinguish pediatric secondary high-grade glioma from primary high-grade glioma.
A history of hormonal contraceptive use in younger women for 5 years or more was found to be associated with a possible increased risk of glioma.
As our understanding of tumor biology grows, we may identify targeted agents that can be used to treat low-grade gliomas. One such approach moving into clinical trials is the use of IDH inhibitors.
In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas-the three most heavily encountered and studied of the low-grade gliomas.
The recent evidence that incorporation of chemotherapeutic interventions can result in relatively long survival times for patients with low-grade glioma highlights the need to also preserve neurocognitive function and health-related quality of life in these patients.
There have been and continue to be areas of uncertainty surrounding the treatment of grade II gliomas. One in particular is the optimal timing of treatment.
